Which agent is used to decrease arrhythmias in DCM management?

In the management of dilated cardiomyopathy (DCM), low-dose antiarrhythmics are utilized to decrease the incidence and severity of arrhythmias. DCM often leads to structural and electrical changes in the heart, which can predispose patients to various types of arrhythmias. Antiarrhythmic medications are designed to stabilize the heart's electrical activity, control heart rate, and restore normal rhythm, thereby reducing symptoms and improving overall cardiac function.

While digoxin, beta-blockers, and anticoagulants like warfarin play important roles in the management of heart failure and prevention of thromboembolic events, they do not specifically target the reduction of arrhythmias in the same direct way that low-dose antiarrhythmics do. For instance, beta-blockers can help with heart rate control and may have some antiarrhythmic effects, but their primary use is more focused on rate control and heart failure management. Similarly, digoxin can help with heart failure symptoms but is not primarily aimed at addressing arrhythmias directly.

Therefore, low-dose antiarrhythmics stand out as the preferred agents specifically designed to target and decrease arrhythmias in patients with DCM.